ARCT Earnings

ARCT reported its FY2025Q4 earnings on 2026-03-03, showcasing a revenue of against an estimate of 14.37M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.92 by 0%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following ARCT's FY2025Q4 earnings announcement on 2026-03-03, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, ARCT's stock price tends to shift by an average of 10.48% in the 10 days leading up to earnings and 5.65% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate ARCT's annual revenue to reach 14.17M, while the EPS is projected at -0.79. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between ARCT's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ARCT's stock price typically moves by 10.48% in the 10 days before its earnings and 5.65% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.79 and revenue of 14.17M.

The earnings call summary and Q&A reveal mixed signals. While there are positive developments in product pipelines and regulatory progress, management's lack of specific guidance on revenue and clinical endpoints creates uncertainty. The Q&A highlighted potential for growth but also pointed to uncertainties in clinical trial outcomes and commercial revenues. No major catalysts like new partnerships or strong financial metrics were announced, leading to a neutral sentiment overall.